Sanuwave Inc. finally won de novo approval for its Dermapace diabetic foot ulcer treatment technology after years of struggling to get the device to the U.S. market. The Alpharetta, Ga.-based company's Dermapace uses high-energy acoustic pressure waves in the shock wave spectrum to produce compressive and tensile stresses on cells and tissue structures to elicit a series of biological responses, such as the formation of new blood vessels and the subsequent regeneration of tissue.